IRHOR Iron Horse latest quarterly earnings filing omits core financial metrics and formal forward guidance Amgen Inc AMGN Sustained Biotech Sector Outperformance Backed by MoatLike Competitive Advantages KYMR Kymera Therapeutics posts wider than expected Q4 2025 loss sending shares down 259 percent today